A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?
ALevel 1
BLevel 3
CLevel 5
DLevel 4
ELevel 2
A research group designed a study to investigate the epidemiology of syphilis in the United States. The investigators examined per capita income and rates of syphilis in New York City, Los Angeles, Chicago, and Houston. Data on city-wide syphilis rates was provided by each city's health agency. The investigators ultimately found that the number of new cases of syphilis was higher in low-income neighborhoods. This study is best described as which of the following?
ADouble-blind clinical trial
BProspective cohort study
CCase-control study
DCase series
EEcological study
A scientist is studying the characteristics of a newly discovered infectious disease in order to determine its features. He calculates the number of patients that develop the disease over several months and finds that on average 75 new patients become infected per month. Furthermore, he knows that the disease lasts on average 2 years before patients are either cured or die from the disease. If the population being studied consists of 7500 individuals, which of the following is the prevalence of the disease?
A0.24
B0.02
C0.12
D0.005
E0.01
+ 7 more in the PDF
Browse all chapters